On 8 January 2025, Astellas Pharma announced that China’s National Medical Products Administration (NMPA) has approved its Padcev™ (enfortumab vedotin) in combination with Merck’s (known as MSD outside the US and Canada) Keytruda® (pembrolizumab) for adult patients with locally advanced or metastatic urothelial cancer.
The combination therapy has received several approvals over the past 12 months, including in the UK (October 2024) the EU (September 2024), Japan (September 2024), Canada (August 2024), and the US (December 2023).